keyword
https://read.qxmd.com/read/37964102/ternary-deep-eutectic-solvents-system-of-colchicine-4-hydroxyacetophenone-and-protocatechuic-acid-and-characterization-of-transdermal-enhancement-mechanism
#1
JOURNAL ARTICLE
Huiqing Piao, Wanchen Xie, Shiqi Li, Jiaqi Wang, Chao Liu, Peng Quan, Liang Fang
This study aimed to prepare colchicine (CO), 4-hydroxyacetophenone (HA), and protocatechuic acid (CA) contained in transdermal rubber plasters into a more releasable and acrylate pressure-sensitive adhesive (PSA) to optimize traditional Touguling rubber plasters (TOU) with enhanced transdermal permeability by using deep eutectic solvents (DES) technology. We compared the difference in the release behavior of CO between rubber plaster and PSA, determined the composition of the patch through pharmacodynamic experiments, explored the transdermal behavior of the three components, optimized the patch formula factors, and improved the penetration of CO through the skin...
November 14, 2023: AAPS PharmSciTech
https://read.qxmd.com/read/36334391/integration-of-transdermal-chemistry-and-network-pharmacology-to-decipher-the-mechanism-of-shexiangzhuifeng-analgesic-plaster-to-treat-rheumatoid-arthritis
#2
JOURNAL ARTICLE
Jie Wang, Qi Chen, Ruilin Sheng, Ping Li, Panwang Liu, Jie Luo, Zhanqiong Zhong, Shijun Xu
BACKGROUND: Transdermal patches are an effective form of treatment for rheumatoid arthritis (RA), and they have a number of benefits, including patient compliance, accessibility, and low systemic toxicity. ShexiangZhuifeng Analgesic Plaster (SZAP), a patch made up of many traditional medicines, has been successfully utilized in numerous clinical trials to treat RA. However, information about anti-RA processes and transdermal active components is still emerging. PURPOSE: Our objectives were to identify the transdermal active components of SZAP and investigate its anti-RA mechanisms, primarily focused on joint inflammation...
October 18, 2022: Phytomedicine
https://read.qxmd.com/read/34813879/recent-advances-in-polymeric-transdermal-drug-delivery-systems
#3
REVIEW
Farzaneh Sabbagh, Beom Soo Kim
Transdermal delivery has proven to be one of the most favorable methods among novel drug delivery systems. Since drugs administered by transdermal delivery systems avoid the gastrointestinal tract, and thus avoid conversion by the liver, the likelihood of liver dysfunction and gastrointestinal tract irritation as side effects is low. Drug delivery through the skin has other advantages, such as maintaining an effective rate of drug delivery over time, a steady rate of circulation, and the benefits of a passive delivery system and diffusion...
November 20, 2021: Journal of Controlled Release
https://read.qxmd.com/read/30236552/design-of-in-vitro-skin-permeation-studies-according-to-the-ema-guideline-on-quality-of-transdermal-patches
#4
JOURNAL ARTICLE
Francesco Cilurzo, Umberto M Musazzi, Silvia Franzé, Guido Fedele, Paola Minghetti
Transdermal patches and medicated plasters are designed to sustain efficacious systemic or loco-regional drug concentrations, respectively. In both cases, drug skin permeation is a critical attribute from the early stage of the pharmaceutical development. In 2014, the EMA introduced the "Guideline on the quality of transdermal patches", in which the importance of equivalence of drug fluxes in in vitro skin permeation study was particularly emphasized to generic or abridged applications for the marketing authorization or manage dossier variations during the product cycle life...
December 1, 2018: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/30183253/enhanced-transdermal-drug-delivery-by-transfersome-embedded-oligopeptide-hydrogel-for-topical-chemotherapy-of-melanoma
#5
JOURNAL ARTICLE
Tianyue Jiang, Tong Wang, Teng Li, Yudi Ma, Shiyang Shen, Bingfang He, Ran Mo
Topical administration of anticancer drugs provides a potential chemotherapeutic modality with high patient compliance for cutaneous melanoma. However, the drug delivery efficiency is highly limited by physiological barriers from the skin to the tumor, which cannot acquire desired therapeutic efficacy. Herein, we propose a paintable oligopeptide hydrogel containing paclitaxel (PTX)-encapsulated cell-penetrating-peptide (CPP)-modified transfersomes (PTX-CTs) to enhance transdermal PTX delivery for topical melanoma treatment...
October 23, 2018: ACS Nano
https://read.qxmd.com/read/26629480/the-effect-of-transdermal-nitroglycerin-on-pain-control-in-diabetic-patients-with-peripheral-neuropathy
#6
JOURNAL ARTICLE
Arman Taheri, Arash Farbood, Ramin Heshmat, Afshin Samadi, Patricia Khashayar, Mostafa Qorbani, Mohammad Ghorbani, Ghazaleh Ebrahimi Khaneqah
BACKGROUND: Despite high prevalence of diabetic peripheral neuropathy there is no definite treatment for the condition. The present study was conducted to assess the efficacy of transdermal nitroglycerin patch in pain control of patients with DPN. METHODS: This randomized, double-blind, crossover study was conducted on 30 patients with symmetric distal peripheral neuropathy and good glycemic control. The patients were randomly assigned to receive nitroglycerin transdermal and placebo patches in two 4-week stages...
2015: Journal of Diabetes and Metabolic Disorders
https://read.qxmd.com/read/26084835/-in-process-citation
#7
JOURNAL ARTICLE
Béla Kiss, Mátyás Papp, Tamás Bödecs, László Kecskés
OBJECTIVE: The authors examined pain after thoracotomies in the Department of Thoracic Surgery, University Teaching Hospital Markusovszky and compared two analgetic methods. PATIENTS AND METHOD: The study was conducted for a period of 10 months, they have processed 268 patients details whose chest were open. The patients were divided in 2 groups: one of them got fentanyl containing plaster which absorbs transdermal as well as intraoperatively applied intercostal bupivacain blockade...
June 2015: Magyar Sebészet
https://read.qxmd.com/read/24988084/-localized-neuropathic-pain-5-lidocaine-medicated-patch-as-a-first-line-treatment-and-as-add-on-therapy-literature-review-and-personal-experience
#8
REVIEW
R Casale, E Polati, V Schweiger, F Coluzzi, A Bhaskar, M Consalvo
Localized neuropathic pain (LNP) is a type of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain, which are associated with negative or positive sensory signs and/or spontaneous symptoms typical of neuropathic pain. This description outlines the clinical features of a group of pathologies, in which a LNP can be diagnosed and for whom topical targeted treatment with 5% Lidocaine medicated plaster can be suggested. Indeed both American as well as European guidelines already suggest 5% Lidocaine medicated plaster as a first line treatment in post herpetic neuralgia and in general in the treatment of conditions such as diabetic painful polyneuropathy and post surgical pain where a LNP can be ascertain...
June 2014: Minerva Medica
https://read.qxmd.com/read/24829815/fatal-overdose-due-to-confusion-of-an-transdermal-fentanyl-delivery-system
#9
JOURNAL ARTICLE
Ingo Voigt
Background. The use of transdermal fentanyl systems has increased over recent years, especially in patients with chronic pain. Large misuse potential and fatal outcomes have been described. Case Presentation. A 58-year-old patient presenting with clinical signs of opioid poisoning (hypoventilation, bradycardia, hypotension, and miosis) was admitted to our ICU. The first body check revealed a 75 mcg per hour fentanyl patch at the patient's right scapula. Some months ago, patient's aunt died after suffering from an oncological disease...
2013: Case Reports in Critical Care
https://read.qxmd.com/read/24766369/application-of-methyl-methacrylate-copolymers-to-the-development-of-transdermal-or-loco-regional-drug-delivery-systems
#10
REVIEW
Francesco Cilurzo, Francesca Selmin, Chiara G M Gennari, Luisa Montanari, Paola Minghetti
INTRODUCTION: Methyl methacrylate copolymers (Eudragit®) have been exploited to develop transdermal patches, medicated plasters (hereinafter patches) and, more recently, film-forming sprays, microsponges and nanoparticles intended to be applied on the skin. AREAS COVERED: The article reviews the information regarding the application of Eudragits in the design and development of these dosage forms focusing on the impact of formulative variables on the skin drug penetration and the patch adhesive properties...
July 2014: Expert Opinion on Drug Delivery
https://read.qxmd.com/read/24289500/treatment-of-neuropathic-pain-with-the-capsaicin-8-patch-is-pretreatment-with-lidocaine-necessary
#11
COMPARATIVE STUDY
Kai-Uwe Kern, Walburga Nowack, Chris Poole
The capsaicin 8% patch can effectively treat neuropathic pain, but application can cause discomfort or a burning sensation. Until March 2013, it was recommended that patients be pretreated with a topical anesthetic, for example lidocaine, before capsaicin patch application. However, speculation existed over the need for pretreatment and its effectiveness in alleviating treatment-associated discomfort. This article compares tolerability to and efficacy of the capsaicin patch in pretreated and non-pretreated patients...
February 2014: Pain Practice: the Official Journal of World Institute of Pain
https://read.qxmd.com/read/24220504/golden-plaster-for-pain-therapy-in-patients-with-knee-osteoarthritis-study-protocol-for-a-multicenter-randomized-double-blind-placebo-controlled-trial
#12
RANDOMIZED CONTROLLED TRIAL
Jin-Tao Liu, De-Zhi Tang, Xiao-Feng Li, Zhi-Gang Zhang, Wan-Bo Ji, Shuai Tao, Yong-Jun Wang, Hong Jiang
BACKGROUND: Osteoarthritis is a relatively common musculoskeletal disorder that increases in prevalence with age. Worldwide, knee osteoarthritis is one of the leading causes of disability, particularly in the elderly. In numerous trials of agents for long-term pain therapy, no well-established and replicable results have been achieved. Complementary and alternative medical approaches have been employed for thousands of years to relieve knee osteoarthritis pain. Among herbal medicines, the golden plaster is the preferred and most commonlyused method in China to reduce pain in patients with knee osteoarthritis, as it causes few adverse effects...
2013: Trials
https://read.qxmd.com/read/24164486/on-the-characterization-of-medicated-plasters-containing-nsaids-according-to-novel-indications-of-usp-and-ema-adhesive-property-and-in-vitro-skin-permeation-studies
#13
JOURNAL ARTICLE
Francesco Cilurzo, Chiara G M Gennari, Francesca Selmin, Silvia Franzé, Umberto M Musazzi, Paola Minghetti
Abstract This work aims to establish if the assays recently introduced by EMA (Guideline on quality of transdermal patches-draft) and USP (Specific tests for transdermal delivery systems) to characterize transdermal patches (TP) are suitable for medicated plasters (MP). Six approved MP differing for type and characteristics of adhesive and backing layer were selected and characterized in terms of adhesive performances by tack, shear adhesion, peel adhesion and release liner removal tests and in vitro skin permeation...
February 2015: Drug Development and Industrial Pharmacy
https://read.qxmd.com/read/23551197/an-exploratory-microdialysis-study-investigating-the-effect-of-repeated-application-of-a-diclofenac-epolamine-medicated-plaster-on-prostaglandin-concentrations-in-skeletal-muscle-after-standardized-physical-exercise
#14
JOURNAL ARTICLE
Angela Burian, Valeria Frangione, Stefano Rovati, Giuseppe Mautone, Chiara Leuratti, Angelo Vaccani, Richard Crevenna, Mohammad Keilani, Bernhard Burian, Martin Brunner, Markus Zeitlinger
AIM: Muscle injuries and extensive exercise are associated with cyclo-oxygenase dependent formation of inflammatory prostaglandins. Since the effect of topical administration of non-steroidal anti-inflammatory drugs (NSAIDs) on local cyclo-oxygenase is unknown, the present exploratory, open label, non-randomized study set out to measure exercise induced release of prostaglandins before and after epicutaneous administration of diclofenac. METHODS: Microdialysis was used to determine the local interstitial concentration of PGE2 and 8-iso-PGF2α as well as diclofenac concentrations in the vastus lateralis under rest, dynamic exercise and during recovery in 12 healthy subjects at baseline and after a treatment phase applying a total of seven plasters medicated with 180 mg of diclofenac epolamine over 4 days...
December 2013: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/23138838/design-and-in-vitro-evaluation-of-transdermal-patches-based-on-ibuprofen-loaded-electrospun-fiber-mats
#15
JOURNAL ARTICLE
Yongli Shi, Shuxin Xu, Anjie Dong, Jianhua Zhang
To improve the poor compatibility among different components of Drug-in-adhesive type patch, two novel plasters (Drug-in-fiber and Drug-in-adhesive/fiber) were developed based on ibuprofen (IBU)-loaded fiber mats. These fibrous mats were fabricated via electrospinning of cellulose acetate/poly(vinylpyrrolidone) composites in a binary solvent of N,N-dimethyl acetamide/acetone. Physical status studies suggested that Drug-in-fiber could inhibit IBU re-crystallization, but the active ingredients were released at a relatively slow rate due to the dual-resistance of fiber mat and adhesive matrix...
February 2013: Journal of Materials Science. Materials in Medicine
https://read.qxmd.com/read/22171789/adhesive-properties-a-critical-issue-in-transdermal-patch-development
#16
REVIEW
Francesco Cilurzo, Chiara G M Gennari, Paola Minghetti
INTRODUCTION: Transdermal patches and medicated plasters (patch) represent well-established prolonged release dosage forms. Even if satisfactory adhesion to the skin is strictly linked to the efficacy and safety of the therapeutic treatment, nowadays numerous reports of in vivo 'adhesion lacking' are still addressed to regulatory agencies. The adhesive properties of a patch should be characterized considering i) the ability to form a bond with the surface of another material on brief contact and under light pressure (tack); ii) the resistance of the adhesive to flow (shear adhesion); and iii) the force required to peel away a patch from a surface (peel adhesion)...
January 2012: Expert Opinion on Drug Delivery
https://read.qxmd.com/read/21877907/disaster-after-the-plaster-fentanyl-withdrawal-symptoms-in-a-curable-hospice-patient
#17
JOURNAL ARTICLE
M Hugo J Maathuis, Daniel D P Dijkstra
Opioids have been used for thousands of years for pain relief. Transdermal fentanyl (TDF) is a synthetic opioid that is prescribed for the treatment of chronic pain. This clinical lesson demonstrates that TDF may be easy to start but sometimes difficult to stop. Like any other opioid there is a substantial risk of physical dependence and subsequent withdrawal symptoms after discontinuation of the drug. Here, we present a case of a hospice patient who developed withdrawal symptoms after a first TDF tapering attempt according to the manufacturer's instructions...
December 2011: European Journal of General Practice
https://read.qxmd.com/read/20923251/diclofenac-epolamine-plus-heparin-plaster-versus-diclofenac-epolamine-plaster-in-mild-to-moderate-ankle-sprain-a-randomized-double-blind-parallel-group-placebo-controlled-multicentre-phase-iii-trial
#18
RANDOMIZED CONTROLLED TRIAL
Cosimo Costantino, Jacek Kwarecki, Anatoly V Samokhin, Giuseppe Mautone, Stefano Rovati
BACKGROUND: In general sports, ankle sprain is the most frequently reported ankle injury and can cause chronic lateral ankle pain and tenderness. Treatment with NSAIDs is preferred, and several topical NSAID formulations are now available, helping to avoid the systemic adverse events typically associated with oral preparations. OBJECTIVE: To compare the efficacy and tolerability of a newly developed fixed-dose diclofenac epolamine (diclofenac hydroxyethylpyrrolidine, DHEP)/heparin plaster (Flectoparin® Tissugel) with that of a DHEP (Flector EP Tissugel®) or placebo plaster in the treatment of mild to moderate ankle sprain in adults...
2011: Clinical Drug Investigation
https://read.qxmd.com/read/16719539/transdermal-scopolamine-for-prevention-of-motion-sickness-clinical-pharmacokinetics-and-therapeutic-applications
#19
REVIEW
Zohar Nachum, Avi Shupak, Carlos R Gordon
A transdermal therapeutic system for scopolamine (TTS-S) was developed to counter the adverse effects and short duration of action that has restricted the usefulness of scopolamine when administered orally or parenterally. The plaster contains a reservoir of 1.5 mg of scopolamine programmed to deliver 0.5 mg over a 3-day period. A priming dose (140 microg) is incorporated into the adhesive layer to saturate certain binding sites within the skin and to accelerate the achievement of steady-state blood levels...
2006: Clinical Pharmacokinetics
https://read.qxmd.com/read/16175141/pharmacokinetics-and-pharmacodynamics-in-clinical-use-of-scopolamine
#20
REVIEW
Ulf D Renner, Reinhard Oertel, Wilhelm Kirch
The alkaloid L-(-)-scopolamine [L-(-)-hyoscine] competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, antiemetic, and amnestic effects. The parasympatholytic scopolamine, structurally very similar to atropine (racemate of hyoscyamine), is used in conditions requiring decreased parasympathetic activity, primarily for its effect on the eye, gastrointestinal tract, heart, and salivary and bronchial secretion glands, and in special circumstances for a CNS action...
October 2005: Therapeutic Drug Monitoring
keyword
keyword
121071
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.